title: Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction.
abstract: OBJECTIVE
  We prospectively investigated the prognostic value of pentraxin 3 (PTX3) in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI).
  
  
  BACKGROUND
  PTX3 may be a useful marker for localized vascular inflammation and damage to the cardiovascular system. Recent studies have shown that plasma PTX3 is elevated in patients with UA/NSTEMI; however, its prognostic value in UA/NSTEMI remains unclear.
  
  
  METHODS
  PTX3, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac troponin I were measured on admission in 204 consecutive patients (mean age of 69 years; 144 males) hospitalized for UA/NSTEMI within 24h (mean of 7.5h) after the onset of chest symptoms. A cardiac event, which was defined as cardiac death, rehospitalization for acute coronary syndrome (ACS), or rehospitalization for worsening heart failure, was monitored for 6 months after admission.
  
  
  RESULTS
  A total of 26 (13%) cardiac events occurred during the 6-month follow-up period. In a stepwise Cox regression analysis including 18 well-known clinical and biochemical predictors of ACS outcome, both PTX3 (relative risk 3.86 per 10-fold increment, P=0.01) and NT-proBNP (relative risk 2.16 per 10-fold increment, P=0.02), but not hsCRP, were independently associated with the 6-month cardiac event. The cardiac event rate was higher in patients with increased PTX3 (> or = 3.1ng/mL of median value) than those without (20% vs. 5.8%, P=0.003). A Kaplan-Meier analysis revealed that patients with increased PTX3 had a higher risk for cardiac events than those without (P=0.002).
  
  
  CONCLUSIONS
  PTX3 and NT-proBNP may be potent and independent predictors for 6-month cardiac events in patients hospitalized for UA/NSTEMI within 24h after the onset. Measurement of plasma PTX3 may substantially improve the early risk stratification of patients with UA/NSTEMI.
authors: Division of Critical Care, Fujita Health University Graduate School of Health Sciences, Fujita Health University, Toyoake, Japan.
authors: Shigeru
authors: S
authors: Matsui
authors: Junnichi
authors: J
authors: Ishii
authors: Fumihiko
authors: F
authors: Kitagawa
authors: Atsuhiro
authors: A
authors: Kuno
authors: Kousuke
authors: K
authors: Hattori
authors: Makoto
authors: M
authors: Ishikawa
authors: Masanori
authors: M
authors: Okumura
authors: Shino
authors: S
authors: Kan
authors: Tadashi
authors: T
authors: Nakano
authors: Hiroyuki
authors: H
authors: Naruse
authors: Ikuko
authors: I
authors: Tanaka
authors: Masanori
authors: M
authors: Nomura
authors: Hitoshi
authors: H
authors: Hishida
authors: Yukio
authors: Y
authors: Ozaki
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D005260:Female; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000097:blood* / Q000503:physiopathology; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D011379:Prognosis; D000683:Serum Amyloid P-Component / Q000032:analysis*; D014336:Troponin / Q000097:blood; D000099153:Pentraxins
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein; D020097:Natriuretic Peptide, Brain; D010446:Peptide Fragments; D000683:Serum Amyloid P-Component; D014336:Troponin; D000099153:Pentraxins; C109794:pro-brain natriuretic peptide (1-76)